CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 71 enrolled
Drug / intervention
TDM-105795, 0.0025% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05802173
NCT05802173Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects With Androgenetic Alopecia

Technoderma Medicines Inc.·interventional·Posted Apr 6, 2023·Updated Nov 12, 2025

In Brief

A Phase 2 clinical trial evaluating TDM-105795, 0.0025%, TDM-105795, 0.02%, and 1 other intervention for Alopecia, Androgenetic. Completed, enrolled 71 participants across 13 sites.

Detailed Summary

Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia, Androgenetic
CountriesUnited States
CollaboratorsTherapeutics, Inc.

Timeline

Phase 2CompletedFinished
202420252026
First PostedApr 6, 2023
Enrollment StartMar 6, 2023
Primary CompletionNov 8, 2023
Study CompletionJan 29, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.2 years ago

Interventions

TDM-105795, 0.0025%drug

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

TDM-105795, 0.02%drug

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

TDM-105795 topical vehicle solutiondrug

The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.